Patent · US Active

Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma

US10954300B2 · kind B2 · utility

0Cited by

35References

16Claims

0Family size

Assignee

The Trustees of Columbia University in the City of New York · US

Inventors

Sankar Ghosh · Madison, US
Yenkel Grinberg-Bleyer · New York, US

Key dates

Filing date	Sep 28, 2016
Grant date	Mar 23, 2021
Priority date	—
Expiry date	Sep 28, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Methods of treating a PD-1-resistant cancer are provided and comprise administering to a subject in need thereof a therapeutically effective amount of a c-Rel inhibitor and a therapeutically effective amount of a PD-1 inhibitor. A pharmaceutical combination comprising a therapeutically effective amount of a c-Rel inhibitor, and a therapeutically effective amount of a PD-1 inhibitor is also provided. Finally, methods of treating a cancer such as a CTLA-4-resistant cancer, a CD137-resistant cancer, and an OX-4-resistant cancer are provided and comprise administering to a subject in need thereof a therapeutically effective amount of a c-Rel inhibitor and a therapeutically effective amount of a CLTA-4, CD137 or OX-4 inhibitor, respectively.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.